3-Bromopyruvate: A novel antifungal agent against the human pathogen Cryptococcus neoformans

Biochemical and Biophysical Research Communications

Volumn 434, Issue 2, 2013, Pages 322-327

  Dylag, Mariusz ^a   Lis, Paweł ^a   Niedźwiecka, Katarzyna ^a   Ko, Young H ^b   Pedersen, Peter L ^c   Goffeau, Andre ^d   Ułaszewski, Stanisław ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b UM BioPark   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

3 Bromopyruvate; Antifungal activity; Cryptococcus neoformans

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BROMOPYRUVIC ACID; FLUCONAZOLE; GLUTATHIONE; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CELL VIABILITY; CORRELATION ANALYSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG CYTOTOXICITY; FUNGAL STRAIN; FUNGUS GROWTH; GROWTH INHIBITION; HUMAN; INTRACELLULAR SPACE; MAMMAL CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

ADENOSINE TRIPHOSPHATE; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOLOGICAL TRANSPORT; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; GLUTATHIONE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PYRUVATES; TIME FACTORS;

FILOBASIDIELLA NEOFORMANS; FUNGI; MAMMALIA; SACCHAROMYCES CEREVISIAE;

EID: 84877070163     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.125     Document Type: Article

References (34)

1. Huston S.M., Mody C.H. Cryptococcosis: an emerging respiratory mycosis. Clin. Chest Med. 2009, 30:253-264.
2. Del Poeta M., Casadevall A. Ten challenges on Cryptococcus and cryptococcosis. Mycopathologia 2012, 173:303-310.
3. Rajasingham R., Rolfes M.A., Birkenkamp K.E., et al. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLOS Med. 2012, 9:e1001316.
4. Park B.J., Wannemuehler K.A., Marston B.J., et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
5. Laniado-Laborin R., Cabrales-Vargas M.N. Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 2009, 26:223-227.
6. Loyse A., Wilson D., Meintjes G., et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 2012, 54:121-128.
7. Vermes A., Guchelaar H.-J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000, 46:171-179.
8. Sionov E., Lee H., Chang Y.C., et al. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLOS Pathog. 2010, 6:e1000848.
9. Cannon R.D., Lamping E., Holmes A.R., et al. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 2009, 22:291-321.
10. Ko Y.H., Pedersen P.L., Geschwind J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001, 173:83-91.
11. Ko Y.H., Smith B.L., Wang Y., et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 2004, 5:269-275.
12. Buijs M., Vossen J.A., Geschwind J.F., et al. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest. New Drug 2009, 27:120-123.
13. Mathupala S.P., Ko Y.H., Pedersen P.L. The pivotal roles of mitochondria in cancer: warburg and beyond and encouraging prospects for effective therapies. Biochim. Biophys. Acta 2010, 1797:1225-1230.
14. Schaefer N.G., Geschwind J.F., Engles J., et al. Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. Transl. Res. 2012, 159:51-57.
15. Lis P., Zarzycki M., Ko Y.H., et al. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. J. Bioenerg. Biomembr. 2012, 44:155-161.
16. Goffeau A. Drug resistance: the fight against fungi. Nature 2008, 452:541-542.
17. Prasad R., Goffeau A. Yeast ATP-binding cassette transporters conferring multidrug resistance. Annu. Rev. Microbiol. 2012, 66:39-63.
18. Böhme A., Ruhnke M., Buchheidt D., et al. Treatment of invasive fungal infections in cancer patients - recommendations of the infectious diseases working part (AGIHO) of the German society of hematology and oncology (DGHO). Ann. Hematol. 2009, 88:97-110.
19. Amberg D.C., Burke D.J., Strathern J.N. Methods in Yeast Genetics 2005: A Cold Spring Harbor Laboratory Course Manual 2005, Cold Spring Harbor Laboratory Press, New York. 2005th ed.
20. P.A. Wayne, National Committee for Clinical Laboratory Standards, Reference Methods for Broth Dilution Antifungal Susceptibility Testing of Yeast, Approved Standard M27-A2, NCCLS, 2002.
21. Singh J., Zaman M., Gupta K.A. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med. Mycol. 2007, 45:595-602.
22. Casal M., Paiva S., Andrade R.P., et al. The lactate-proton symport of Saccharomyces cerevisiae is encoded by Jen1. J. Bacteriol. 1999, 181:2620-2623.
23. Reliene R., Schiestl R.H. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis 2006, 27:240-244.
24. Lodi T., Diffels J., Goffeau A., et al. Evolution of the carboxylate Jen transporters in fungi. FEMS Yeast Res. 2007, 7:646-656.
25. Casal M., Paiva S., Queirós O., et al. Transport of carboxylic acids in yeast. FEMS Microbiol. Rev. 2008, 32:974-994.
26. Wang H., Xu Z., Gao L., et al. A fungal phylogeny based on 82 complete genomes using the composition vector method. BMC Evol. Biol. 2009, 9:195.
27. Loftus B.J., Fung E., Roncaglia P., et al. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 2005, 307:1321-1324.
28. Benoist J.F., Alberti C., Leclercq S., et al. Cerebrospinal fluid lactate and pyruvate concentrations and their ratio in children: age-related reference intervals. Clin. Chem. 2003, 49:487-494.
29. Kronstad J., Saikia S., Nielson E.D., et al. Adaptation of Cryptococcus neoformans to mammalian hosts: integrated regulation of metabolism and virulence. Eucaryot. Cell 2012, 11:109-118.
30. Skory C.D., Hector R.E., Gorsich S.W., et al. Report membrane transport of lactic acid in the filamentous fungus Rhizopus. KKU Res. J. 2010, 15:826-831.
31. Zhang Q., Pan J., North P.E., et al. Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev. Res. 2012, 5:717-725.
32. Pocsi I., Prade R.A., Penninckx M.J. Glutathione, altruistic metabolite in fungi. Adv. Microb. Physiol. 2004, 49:1-76.
33. Haimeur A., Conseil G., Deeley R.G., et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate and regulation. Curr. Drug Metab. 2004, 5:21-53.
34. Wortelboer H.M., Balvers M.G., Usta M., et al. Glutathione dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2. Environ. Toxicol. Pharm. 2008, 26:102-108.